$2.73
4.20%
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US30233M1071
Symbol
KPRX

EyeGate Pharmaceuticals, Inc. Stock price

$2.73
-0.30 9.90% 1M
-0.62 18.51% 6M
-0.57 17.27% YTD
-0.97 26.22% 1Y
-42.16 93.92% 3Y
-1,631.67 99.83% 5Y
-21,273.27 99.99% 10Y
-31,857.27 99.99% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.11 4.20%
ISIN
US30233M1071
Symbol
KPRX
Industry

Key metrics

Basic
Market capitalization
$9.4m
Enterprise Value
$-11.3m
Net debt
positive
Cash
$20.7m
Shares outstanding
3.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 4.1
EV/Sales
- | negative
EV/FCF
1.4
P/B
0.4
Financial Health
Equity Ratio
70.6%
Return on Equity
14.0%
ROCE
-38.2%
ROIC
-132.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $2.3m
EBITDA
$-11.0m | -
EBIT
$-11.0m | $-11.0m
Net Income
$-12.0m | $-7.5m
Free Cash Flow
$-7.8m
Growth (TTM | estimate)
Revenue
-100.0% | -85.7%
EBITDA
-511.6% | -
EBIT
-516.8% | -268.3%
Net Income
-548.7% | -308.9%
Free Cash Flow
-265.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -327.0%
Free Cash Flow
-
More
EPS
$-3.0
FCF per Share
$-2.3
Short interest
0.9%
Employees
12
Rev per Employee
$1.3m
Show more

Is EyeGate Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

EyeGate Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a EyeGate Pharmaceuticals, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a EyeGate Pharmaceuticals, Inc. forecast:

Buy
88%
Hold
13%

Financial data from EyeGate Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.55 5.55
8% 8%
-
- Research and Development Expense 11 11
130% 130%
-
-11 -11
512% 512%
-
- Depreciation and Amortization 0.01 0.01
67% 67%
-
EBIT (Operating Income) EBIT -11 -11
517% 517%
-
Net Profit -12 -12
549% 549%
-

In millions USD.

Don't miss a Thing! We will send you all news about EyeGate Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EyeGate Pharmaceuticals, Inc. Stock News

Neutral
The Motley Fool
17 days ago
Kiora (KPRX) Q2 Revenue Falls 100%

Company Profile

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

Head office United States
CEO Brian Strem
Employees 12
Founded 1998
Website kiorapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today